These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

525 related articles for article (PubMed ID: 27324144)

  • 1. Temporal changes in biomarkers and their relationships to reperfusion and to clinical outcomes among patients with ST segment elevation myocardial infarction.
    van Diepen S; Alemayehu WG; Zheng Y; Theroux P; Newby LK; Mahaffey KW; Granger CB; Armstrong PW
    J Thromb Thrombolysis; 2016 Oct; 42(3):376-85. PubMed ID: 27324144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic changes in N-terminal pro-brain natriuretic peptide in acute coronary syndromes treated with percutaneous coronary intervention: a marker of ischemic burden, reperfusion and outcome.
    Buchner S; Debl K; Barlage S; Griese D; Fredersdorf S; Jeron A; Lubnow M; Müller T; Muders F; Holmer S; Riegger GA; Luchner A
    Clin Chem Lab Med; 2010 Jun; 48(6):875-81. PubMed ID: 20441480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of angiographic and electrocardiographic parameters of reperfusion to prediction of mortality and morbidity after acute ST-elevation myocardial infarction: Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial.
    Brener SJ; Westerhout CM; Fu Y; Todaro TG; Moliterno DJ; Wagner GS; Granger CB; Armstrong PW;
    Am Heart J; 2009 Nov; 158(5):755-60. PubMed ID: 19853693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of early myocardial reperfusion and perfusion on myocardial necrosis/dysfunction and inflammation in patients with ST-segment and non-ST-segment elevation acute coronary syndrome: results from the PLATelet inhibition and patients Outcomes (PLATO) trial.
    Batra G; Renlund H; Kunadian V; James SK; Storey RF; Steg PG; Katus HA; Harrington RA; Gibson CM; Budaj A; Siegbahn A; Wallentin L
    Eur Heart J Acute Cardiovasc Care; 2022 Jun; 11(4):336-349. PubMed ID: 35213721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma N-terminal fragment of the prohormone B-type natriuretic peptide concentrations in relation to time to treatment and Thrombolysis in Myocardial Infarction (TIMI) flow: a substudy of the Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT IV-PCI) trial.
    Jarai R; Huber K; Bogaerts K; Droogne W; Ezekowitz J; Granger CB; Sinnaeve PR; Ross AM; Zeymer U; Armstrong PW; Van de Werf FJ;
    Am Heart J; 2010 Jan; 159(1):131-40. PubMed ID: 20102879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trial.
    van Diepen S; Roe MT; Lopes RD; Stebbins A; James S; Newby LK; Moliterno DJ; Neumann FJ; Ezekowitz JA; Mahaffey KW; Hochman JS; Hamm CW; Armstrong PW; Theroux P; Granger CB
    J Thromb Thrombolysis; 2012 Jul; 34(1):106-13. PubMed ID: 22307842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Biomarkers, ST-Elevation Resolution, and Clinical Outcomes Following Primary Percutaneous Coronary Intervention.
    Shavadia JS; Granger CB; Alemayehu W; Westerhout CM; Povsic TJ; Van Diepen S; Defilippi C; Armstrong PW
    J Am Heart Assoc; 2020 Jul; 9(13):e016033. PubMed ID: 32552321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudy.
    van Diepen S; Newby LK; Lopes RD; Stebbins A; Hasselblad V; James S; Roe MT; Ezekowitz JA; Moliterno DJ; Neumann FJ; Reist C; Mahaffey KW; Hochman JS; Hamm CW; Armstrong PW; Granger CB; Theroux P;
    Int J Cardiol; 2013 Oct; 168(3):2127-33. PubMed ID: 23394896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights into the change in brain natriuretic peptide after ST-elevation myocardial infarction (STEMI): why should it be better than baseline?
    Ezekowitz JA; Théroux P; Welsh R; Bata I; Webb J; Armstrong PW
    Can J Physiol Pharmacol; 2007 Jan; 85(1):173-8. PubMed ID: 17487257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reperfusion after primary angioplasty for ST-elevation myocardial infarction: predictors of success and relationship to clinical outcomes in the APEX-AMI angiographic study.
    Brener SJ; Moliterno DJ; Aylward PE; van't Hof AW; Ruźyllo W; O'Neill WW; Hamm CW; Westerhout CM; Granger CB; Armstrong PW;
    Eur Heart J; 2008 May; 29(9):1127-35. PubMed ID: 18375399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TIMI myocardial perfusion grade and ST-segment resolution in the assessment of coronary reperfusion after primary angioplasty.
    Horszczaruk GJ; Kwasiborski P; Rdzanek A; Filipiak KJ; Kochman J; Opolski G
    Kardiol Pol; 2014; 72(1):27-33. PubMed ID: 23990232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of preprocedural N-terminal pro-brain natriuretic peptide in predicting angiographic no-reflow phenomenon during stent implantation in patients with ST-segment elevation acute myocardial infarction.
    Hong SN; Ahn Y; Hwang SH; Yoon NS; Lee SR; Moon JY; Kim KH; Hong YJ; Park HW; Kim JH; Jeong MH; Cho JG; Park JC; Kang JC
    Am J Cardiol; 2007 Aug; 100(4):631-4. PubMed ID: 17697819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-terminal pro-brain natriuretic peptide improves the C-ACS risk score prediction of clinical outcomes in patients with ST-elevation myocardial infarction.
    He PC; Duan CY; Liu YH; Wei XB; Lin SG
    BMC Cardiovasc Disord; 2016 Dec; 16(1):255. PubMed ID: 27955618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved early risk stratification of patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention using a combination of serum soluble ST2 and NT-proBNP.
    Yu J; Oh PC; Kim M; Moon J; Park YM; Lee K; Suh SY; Han SH; Byun K; Ahn T; Kang WC
    PLoS One; 2017; 12(8):e0182829. PubMed ID: 28796845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of N-terminal pro-B-type natriuretic peptide in the prediction of outcomes in ST-elevation myocardial infarction complicated by cardiogenic shock.
    Sharma YP; Kanabar K; Santosh K; Kasinadhuni G; Krishnappa D
    Indian Heart J; 2020; 72(4):302-305. PubMed ID: 32861389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fo ATP synthase C subunit serum levels in patients with ST-segment Elevation Myocardial Infarction: Preliminary findings.
    Campo G; Morciano G; Pavasini R; Bonora M; Sbano L; Biscaglia S; Bovolenta M; Pinotti M; Punzetti S; Rizzo P; Aquila G; Giorgi C; Ferrari R; Pinton P
    Int J Cardiol; 2016 Oct; 221():993-7. PubMed ID: 27441480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-terminal pro-B-type natriuretic peptide is associated with adverse short-term clinical outcomes in patients with acute ST-elevation myocardial infarction underwent primary percutaneous coronary intervention.
    Kwon TG; Bae JH; Jeong MH; Kim YJ; Hur SH; Seong IW; Cho MC; Seung KB; Jang YS; Park SJ;
    Int J Cardiol; 2009 Apr; 133(2):173-8. PubMed ID: 18281115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NT-proBNP level before primary PCI and risk of poor myocardial reperfusion: Insight from the On-TIME II trial.
    Fabris E; Ten Berg JM; Hermanides RS; Ottervanger JP; Dambrink JHE; Gosselink AM; Sinagra G; Koopmans PC; Giannitsis E; Hamm C; van 't Hof AWJ
    Am Heart J; 2021 Mar; 233():78-85. PubMed ID: 33388289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-terminal pro-brain natriuretic peptide is a biomarker of congestive heart failure and predictive of 30-day untoward clinical outcomes in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.
    Wu CJ; Chang HW; Hung WC; Yang CH; Chen YH; Su CY; Yip HK
    Circ J; 2006 Feb; 70(2):163-8. PubMed ID: 16434809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial.
    Buller CE; Fu Y; Mahaffey KW; Todaro TG; Adams P; Westerhout CM; White HD; van 't Hof AW; Van de Werf FJ; Wagner GS; Granger CB; Armstrong PW
    Circulation; 2008 Sep; 118(13):1335-46. PubMed ID: 18779444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.